Investigation the relationship between weight gain associated with paroxetine use and serotonin 2C receptor

Date

2025-7-11

Author

Özbay, Batuhan

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

1286
views

0
downloads

Cite This

Obesity is one of the most threatening disorders to public health worldwide and the risks it creates may give rise to many other health problems. Depressive disorders are one of the another consequences that concern public health and especially after 2019 SARS-CoV-2 pandemic, they significantly increased prevalence. Medications classified as selective serotonin reuptake inhibitor (SSRIs) are the most prescribed medications for the treatment of depressive disorders. Paroxetin, one of the most prescribed SSRI group medication, is known for its weight gainer properties and it constitutes risk to induce the onset of obesity. However, the molecular mechanisms behind paroxetine-induced weight gain are not fully elucidated. The regulation of energy metabolism and weight gain are mainly controlled by hypothalamus. Hypothalamus exerts its effect on body weight regulation via NPY and POMC neuropeptides, which are known for orectic and anorektic properties. This study mainly aims to research underlying mechanisms behind paroxetine-induced weight gain, focusing on hypothalamus. Besides NPY and POMC neuropeptides, the serotonin 2C receptor (5-HT2C-R), which is mostly expressed in hypothalamus and strongly associated with weight regulation, is also researched to determine whether it regulates weight gain by affecting from elevated serotonin levels as a result of paroxetine treatment. Reversing the paroxetine-induced weight gain with SB 242084 administration, which is neutral 5-HT2C-R antagonist, is another aim of this study. Our recent findings indicate that paroxetine treatment increases NPY expression levels on hypothalamus while decreasing POMC and 5-HT2C-R levels and SB 242084 co-administration appears to successfully reverse side-effects of paroxetine.

Subject Keywords

Weight gain, Paroxetine, Neuropeptide Y, Proopiomelanocortin, Serotonin 2C receptor

URI

https://hdl.handle.net/11511/115158

Collections

Graduate School of Natural and Applied Sciences, Thesis